The prostate is actually one of the few body parts that never stops growing. Which means as men age it will eventually enlarge to the point where it affects urinary and sexual health.
This condition is called Benign Prostatic Hyperplasia, or BPH for short, and it affects 660 million men worldwide and counting.
Unfortunately, the current options for treatment are painful, invasive, and often force patients to trade symptom relief for sexual and urinary compromise and complications. We think that should change.
We believe it will transform the way BPH is treated and create a more enjoyable life for tens of millions of men around the world.
It's called ReFlowTM.
ReFlowTM will be an outpatient procedure offering long-term solution without complications, akin to the simplicity of No-Scalpel vasectomy. The procedure is enabled by Vivifi's novel technology which can be effectively used by any clinical Urologist.
We are in early clinical development of this revolutionary new treatment that will address the root cause of BPH through a non-surgical approach, which we anticipate will provide long-standing relief and without any, or minimal, side effects.
It has been known forever that testosterone is what fuels growth of prostatic conditions - both benign and malignant1,2. That’s why medications for BPH and Prostate Cancer target Testosterone pathways that prevent it from reaching the prostate.
However, medications can result in several, often painful, side effects and existing therapies have high recurrence rates - adding to rising healthcare expenditures.
We believe that our treatment will provide the benefits of all the treatment options without any of these side effects.
*NOTE: This treatment is for investigational use only and is not approved by the FDA for commercial distribution. It is currently under clinical investigation to evaluate its safety and effectiveness.
1. Huggins, Charles. "The etiology of benign prostatic hypertrophy." Bulletin of the New York Academy of Medicine 23.12 (1947): 696.
2. Kumar, Rajendra, et al. "The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications." Nature Reviews Urology 20.5 (2023): 265-278.
Founder & CEO
Head of R&D
Product Development Engineer
Our potential impact is vast, as 40 million men suffer from BPH in the United States alone. As the global population ages, the prevalence of BPH in older men will be a major driver of market growth.
We believe we have the opportunity to not only change the lives of men affected by BPH, but become a substantive player in the treatment market which is valued at over $12 billion dollars.
We are certain that patients and their providers will welcome and embrace our innovative approach.
Vivifi is made up of a team of award-winning engineers and urologists working closely with our clinical advisors, with support from our technical, legal and business advisors.
Our mission is to improve the quality of life of patients with BPH by surpassing the current standard of care to offer freedom and independence to patients.
2450 Holcombe Blvd, Ste 1420, Houston, TX 77021* NOTE: This treatment is for investigational use only and is not approved by the FDA for commercial distribution. It is currently under clinical investigation to evaluate its safety and effectiveness.
